ストックスクリーナーアプリを入手
5.40
0.55%
-0.03
アフターアワーズ：
5.40
Abeona Therapeutics Inc (ABEO) 最新ニュース
(ABEO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ABEO S-8 & SEC Filings - Yahoo! Finance Canada
Abeona Therapeutics stock reiterated at Buy by H.C. Wainwright - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - prnewswire.com
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright - TradingView
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells - Stocktwits
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum - Yahoo Finance
3 Growth Companies With Up To 18% Insider Ownership - simplywall.st
Roth MKM Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $17 - Moomoo
ABEO Should I Buy - Intellectia AI
Abeona Therapeutics Price Target Raised to $30.00/Share From $28.00 by Cantor Fitzgerald - Moomoo
Cantor raises Abeona stock price target on partner drug approval By Investing.com - Investing.com Australia
Cantor Fitzgerald Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Abeona Therapeutics (ABEO) Congratulates Ultragenyx on FDA Appro - gurufocus.com
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week - Benzinga
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - The Manila Times
A gene therapy for Sanfilippo syndrome gets U.S. approval. Abeona helped develop it. - Stock Titan
ABEO Maintained by Cantor Fitzgerald -- Price Target Raised to $30 - gurufocus.com
Investigation launched into Abeona Therapeutics over possible securities fraud after Q2 revenue report. - Pluang
Abeona Therapeutics Price Target Announced at $17.00/Share by Roth Capital - Moomoo
Roth/MKM initiates Abeona Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Roth/MKM initiates Abeona Therapeutics stock with buy rating - Investing.com
Form 8K Abeona Therapeutics Inc For: 15 September By Investing.com - Investing.com Australia
Abeona Therapeutics (NASDAQ: ABEO) Releases Updated Investor Presentation for September 15 H.C. Wainwright Conference - Kalkine Media
Abeona Therapeutics activates eighth treatment center for RDEB therapy By Investing.com - Investing.com Nigeria
Abeona Therapeutics (ABEO) Expands Zevaskyn Treatment Network Am - GuruFocus
Abeona Therapeutics activates eighth treatment center for RDEB therapy - Investing.com India
Abeona Therapeutics Activates University of Florida Health as Eighth Qualified Treatment Center for ZEVASKYN in RDEB - Quiver Quantitative
Abeona Therapeutics® Announces Activation of University of - GlobeNewswire
Abeona Therapeutics Updates Investor Presentation at Conference - The Globe and Mail
ABEO: Strong ZEVASKYN launch, expanding access, and pipeline advances drive growth momentum - TradingView
Abeona Therapeutics (NASDAQ: ABEO) posts new deck for H.C. Wainwright conference - Stock Titan
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com Canada
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
Don't Ignore The Insider Selling In Abeona Therapeutics - simplywall.st
Responsive Playbooks and the ABEO Inflection - Stock Traders Daily
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Australia
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Abeona Therapeutics director Mark Alvino sells $87,966 in shares - Investing.com
Director Mark Alvino Sells 15,000 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) director sells 15,000 shares, still holds 62,065 - Stock Titan
Director plans Abeona (NASDAQ: ABEO) stock sale from equity awards - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Abeona Therapeutics Inc (ABEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Abeona Therapeutics faces securities fraud prob... - Pluang
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):